과제정보
This work was supported by National Research Foundation of Korea (NRF) grants NRF-2021R1A2C3005603, NRF-2017M3A9G7073086, 2022R1A2C1008591, and NRF-2020R1A5A2017323, funded by the Ministry of Science and the ICT; and by grant HI16C1501 from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare.
참고문헌
- Llovet JM, Zucman-Rossi J, Pikarsky E et al (2016) Hepatocellular carcinoma. Nat Rev Dis Primers 2, 16018
- Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 noninferiority trial. Lancet 391, 1163-1173 https://doi.org/10.1016/S0140-6736(18)30207-1
- Llovet JM, Kelley RK, Villanueva A et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7, 6
- Abdel-Rahman O, Abdel-Wahab M, Shaker M, Abdel-Wahab S, Elbassiony M and Ellithy M (2013) Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol 30, 655
- Samalin E, Bouche O, Thezenas S et al (2014) Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. Br J Cancer 110, 1148-1154
- Zhu AX, Stuart K, Blaszkowsky LS et al (2007) Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110, 581-589 https://doi.org/10.1002/cncr.22829
- Li J, Cao F, Yin HL et al (2020) Ferroptosis: past, present and future. Cell Death Dis 11, 88
- Byun JK, Lee S, Kang GW et al (2022) Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma. J Exp Clin Cancer Res 41, 98
- Sun X, Niu X, Chen R et al (2016) Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology 64, 488-500 https://doi.org/10.1002/hep.28574
- Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM and Mangelsdorf DJ (2006) Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126, 789-799 https://doi.org/10.1016/j.cell.2006.06.049
- Ariazi EA, Clark GM and Mertz JE (2002) Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res 62, 6510-6518
- Singh TD, Song J, Kim J et al (2019) A novel orally active inverse agonist of estrogen-related receptor gamma (ERRgamma), DN200434, a booster of NIS in anaplastic thyroid cancer. Clin Cancer Res 25, 5069-5081 https://doi.org/10.1158/1078-0432.ccr-18-3007
- Kim JH, Choi YK, Byun JK et al (2016) Estrogen-related receptor gamma is upregulated in liver cancer and its inhibition suppresses liver cancer cell proliferation via induction of p21 and p27. Exp Mol Med 48, e213
- Kim MJ, Choi YK, Park SY et al (2017) PPARdelta reprograms glutamine metabolism in sorafenib-resistant HCC. Mol Cancer Res 15, 1230-1242 https://doi.org/10.1158/1541-7786.MCR-17-0061
- Alaynick WA (2008) Nuclear receptors, mitochondria and lipid metabolism. Mitochondrion 8, 329-337 https://doi.org/10.1016/j.mito.2008.02.001
- Li ZY, Yang Y, Ming M and Liu B (2011) Mitochondrial ROS generation for regulation of autophagic pathways in cancer. Biochem Biophys Res Commun 414, 5-8 https://doi.org/10.1016/j.bbrc.2011.09.046
- Ni HM, Williams JA, Jaeschke H and Ding WX (2013) Zonated induction of autophagy and mitochondrial spheroids limits acetaminophen-induced necrosis in the liver. Redox Biol 1, 427-432 https://doi.org/10.1016/j.redox.2013.08.005
- Lei G, Zhuang L and Gan B (2021) mTORC1 and ferroptosis: Regulatory mechanisms and therapeutic potential. Bioessays 43, e2100093
- Li W, Gong M, Park YP et al (2021) Lupus susceptibility gene Esrrg modulates regulatory T cells through mitochondrial metabolism. JCI Insight 6, e143540
- Fan W, He N, Lin CS et al (2018) ERRgamma promotes angiogenesis, mitochondrial biogenesis, and oxidative remodeling in PGC1alpha/beta-deficient muscle. Cell Rep 22, 2521-2529 https://doi.org/10.1016/j.celrep.2018.02.047
- Zhang Y, Swanda RV, Nie L et al (2021) mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation. Nat Commun 12, 1589
- Yi J, Zhu J, Wu J, Thompson CB and Jiang X (2020) Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci U S A 117, 31189-31197 https://doi.org/10.1073/pnas.2017152117
- Liu Y, Wang Y, Liu J, Kang R and Tang D (2021) Interplay between MTOR and GPX4 signaling modulates autophagy-dependent ferroptotic cancer cell death. Cancer Gene Ther 28, 55-63